Veru Inc.
VERUHealthcare|Biotechnology|US
$2.12
+0.06 (+2.91%)
DCF Value
$0.66
Tangible Book / Share
$0.93
Cash / Share
$1.04
Clinical Trials (12)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07446998 Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | Obesity & Overweight, Mobility Disability | P2 | Active | 239 | RCT, Double-blind | Enobosarm, Semaglutide (Wegovy) weekly injection |
| NCT05065411 Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer | Metastatic Breast Cancer | P3 | Terminated | 5 | RCT, Single-blind | Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant |
| NCT04869943 Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer | Metastatic Breast Cancer | P3 | Terminated | 52 | RCT, Open-label | Enobosarm, Exemestane |
| NCT04844749 Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent | Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | P3 | Terminated | 105 | RCT, Single-blind | VERU-111, Enzalutamide, Abiraterone |
| NCT04842747 VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study | SARS-CoV Infection | P3 | Completed | 204 | RCT, Double-blind | VERU-111 |
| NCT04843319 To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer | Advanced Prostate Adenocarcinoma | P1P2 | Terminated | 24 | Open-label | VERU-100 |
| NCT03646162 Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer | Prostate Cancer Metastatic | P2 | Completed | 93 | RCT, Double-blind | Veru-944, Placebo |
| NCT04388826 COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | Respiratory Distress Syndrome, Adult | P2 | Completed | 39 | RCT, Double-blind | Veru-111 |
| NCT06282458 Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt | Muscle Loss, Obesity | P2 | Completed | 168 | RCT, Double-blind | Enobosarm, Semaglutide |
| NCT05008510 P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . | Metastatic Triple Negative Breast Cancer | P2 | Withdrawn | — | RCT, Single-blind | Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy Combo |
| NCT03752099 To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer | Metastatic Castration Resistant Prostate Cancer | P1P2 | Terminated | 80 | RCT, Open-label | VERU-111 |
| NCT05079360 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer | Metastatic Breast Cancer | P2 | Withdrawn | — | RCT, Single-blind | Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator |